AI assistant
Cogent Biosciences, Inc. — Director's Dealing 2018
Mar 29, 2018
31688_dirs_2018-03-28_564bb03f-d1a7-47b6-ad9c-5600fec8cbc1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Unum Therapeutics, Inc. (UMRX)
CIK: 0001622229
Period of Report: 2018-03-28
Reporting Person: VASCONCELLES MICHAEL (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.23 | 2025-11-03 | Common Stock (275772) | Direct | |
| Stock Option (Right to Buy) | $9.77 | 2027-10-26 | Common Stock (79611) | Direct | |
| Stock Option (Right to Buy) | $12.00 | 2028-03-16 | Common Stock (80376) | Direct |
Footnotes
F1: 25% of the shares vests on October 20, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
F2: 25% of the shares vests on October 27, 2018, and the remaining shall shares vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
F3: 25% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.